

**Additional information under Art. 12, par. 1, item 4  
of the Ordinance 2 of 09.11.2021 of  
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.  
as of the 31th of March 2026**

**1. Information on the changes in accounting policy during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer.**

The consolidated financial statements of Tchaikapharma High Quality Medicines Inc. have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union.

More detailed information on the company's accounting policies can be found at on item II.1. Basis of preparation of the consolidated financial statements in the Annexes to the consolidated MFR for the period 01.01.2026 - 31.03.2026.

**2. Information about changes in the economic group of the issuer as at 31 March 2026:**  
no changes

**3. Information on the results from organizational changes made within the issuer, such as restructuring, sale of companies from the economic group, in-kind contributions from companies, rental property, long-term investments, and suspension of operation:** no changes

**4. The opinion of the Governing Body on the realization of the published forecasts for the current financial year, taking into account the results of the current quarter, and the information on the factors and circumstances that will affect the achievement of the forecast results at least for the next quarter –** no predicted results.

**5. For the public companies - data on persons holding directly and indirectly at least 5 percent of votes at the general meeting at the end of the quarter and changes in the votes held by persons since the end of the previous quarter:**

SHAREHOLDERS	Shares	/%/	Shares	/%/
	31.03.2026		31.12.2025	
<b>Tihomir Kamenov</b>	83 483 074	/87,05%/	83 483 074	/87,05%/
<b>PLURIBUS S. A. R. L.</b>	6 582 485	/6,86%/	6 582 485	/6,86%/

**6. Information on pending legal, administrative or arbitration procedures relating to liabilities or receivables amounting to at least 10 percent of the company's equity –** no such procedures.

**7. Information on the loans granted by the issuer or its subsidiary, by their subsidiaries, the collateral provided or the liabilities assumed in total to one person or its subsidiary, including related parties, indicating the names or titles and UIC of the person, the nature of the relationship between the issuer or its subsidiaries and the borrower, the amount of outstanding principal, interest rate, date of conclusion of the contract, including additional agreements, repayment period, amount of commitment, specific conditions other than those specified in this provision , as well as the purpose for which they are granted, in case they are concluded as targets: -**

The Group has entered into contract with UNITED BULGARIAN BANK AD, maturing 20.12.2026. Liabilities under these contracts as at 31.03.2026 are in total amount of EUR 3,998 thousand. The interest rates applied range from 2% to 2.2%. Property, plant and equipment are pledged.

The Group is a co-borrower on a loan to Commercial League - Global Pharmacy Centre AD from


UNITED BULGARIAN BANK AD under agreement dated 03.12.2019, maturing 30.09.2028.

The Group is a co-borrower on a loan to Commercial League - Global Pharmacy Centre AD from UNITED BULGARIAN BANK AD under agreement dated 08.08.2022.

The Group is a co-borrower a syndicated bank loan to Commercial League - Global Pharmacy Centre AD from EUROBANK BULGARIA AD and FIRST INVESTMENT BANK AD under an agreement dated 04.11.2024 in the amount of EUR 41,790 thousand maturing on 30.10.2034.

The Group is a co-borrower on a loan to Commercial League - Global Pharmacy Centre AD from UniCredit Bulbank AD under an agreement dated 20.11.2025, maturing on 15.12.2029, with liabilities as at 31.03.2026.

The Group is a co-borrower on a loan to Commercial League - Global Pharmacy Centre AD from UniCredit Bulbank AD under an agreement dated 20.11.2025, maturing on 29.02.2032, with liabilities as at 31.03.2026.



---

Biser Georgiev  
Executive Director